Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from INBX

Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and dee

MarketBeat · May 11

Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?

Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?

Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose 75.95% in after-hours trading on Thursday, closing at $49.90.

Benzinga · Oct 24, 2025

Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

Inhibrx Inc (NASDAQ:INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it. …

Benzinga · May 16, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play